1 Genetic and potential antigenic evolution of influenza A(H1N1)pdm09 viruses circulating

2 in Kenya during 2009-2018 influenza seasons

- 3 D. Collins Owuor^{1*}, Zaydah R. de Laurent¹, Bryan O. Nyawanda², Gideon O. Emukule³,
- 4 Rebecca Kondor⁴, John R. Barnes⁴, D. James Nokes^{1,5}, Charles N. Agoti^{1,6} and Sandra S.
- 5 Chaves ^{3,4}
- 6

7 Affiliations

- Epidemiology and Demography Department, Kenya Medical Research Institute
 (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya.
- 10 2. Kenya Medical Research Institute, Kisumu, Kenya.
- 11 *3. Influenza Division, Centers for Disease Control and Prevention, Nairobi, Kenya.*
- Influenza Division, National Center for Immunization and Respiratory Diseases
 (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- 14 5. School of Life Sciences and Zeeman Institute for Systems Biology and Infectious
- 15 Disease Epidemiology Research (SBIDER), University of Warwick, Coventry, UK.
- 16 6. School of Public Health and Human Sciences, Pwani University, Kilifi, Kenya.
- 17

18 * Corresponding author. Dr. D. Collins Owuor (<u>collinsdowuor@gmail.com</u>).

19

20 Keywords: Influenza; next-generation sequencing; hemagglutinin; antigenic evolution;
21 genetic groups.

- 22
- 23
- 24

25 Abstract

Background. Influenza viruses undergo rapid evolutionary changes, which requires
continuous surveillance to monitor for genetic and potential antigenic changes in circulating
viruses that can guide control and prevention decision making.

29

Methods. We sequenced and phylogenetically analyzed A(H1N1)pdm09 virus genome sequences obtained from specimens collected from hospitalized patients of all ages with or without pneumonia between 2009 and 2018 from seven sentinel surveillance sites across Kenya. We compared these sequences with recommended vaccine strains during the study period to infer genetic and potential antigenic changes in circulating viruses and determinants of clinical outcome.

36

37 **Results.** We generated and analyzed a total of 383 A(H1N1)pdm09 virus genome sequences. 38 Phylogenetic analyses revealed that multiple genetic groups (clades, subclades, and subgroups) 39 of A(H1N1)pdm09 virus circulated in Kenya over the study period; these evolved away from 40 their vaccine strain, forming clades 7 and 6, subclades 6C, 6B, and 6B.1, and subgroups 6B.1A 41 and 6B.1A1. Several amino acid substitutions among circulating viruses were associated with 42 continued evolution of the viruses, especially in antigenic epitopes and receptor binding sites 43 (RBS) of circulating viruses. Disease severity reduced with increase in age among children 44 aged <5 years.

45

46 **Conclusion.** Our study highlights the utility of genomic surveillance to monitor the 47 evolutionary changes of influenza viruses. Routine influenza surveillance with broad 48 geographic representation and whole genome sequencing capacity to inform on the severity of 49 circulating strains could improve selection of influenza strains for inclusion in vaccines.

51 Introduction

52 The first pandemic of the 21st century was a result of an influenza A virus (IAV) designated 53 A(H1N1)pdm09 virus, which emerged in North America during March-April 2009 and spread 54 rapidly among humans [1-3]. A(H1N1)pdm09 virus displaced seasonal A(H1N1) virus and has 55 continued to circulate in subsequent years alongside influenza A(H3N2) and B viruses globally 56 [4-6], causing annual seasonal epidemics [7-9]. The rapid ability of the virus to spread globally 57 upon its emergence highlights the public health threat posed by emergent viruses [3, 10, 11]. 58 The countrywide surveillance for influenza viruses among medically-attended patients in 59 Kenya since the emergence of the A(H1N1)pdm09 virus strain allows for exploring the 60 phenotypic characteristics of the virus [7, 12, 13]. 61

We characterized the genetic and antigenic evolution in A(H1N1)pdm09 viruses circulating in Kenya between 2009 and 2018 using codon-complete gene sequences generated through nextgeneration sequencing (NGS). We then utilized genetic sequence data and available clinical information to investigate determinants of clinical outcome among hospitalized children aged <5 years.

67

68 Materials and Methods

69 Study design. Samples analyzed in this study were collected between June 2009 and 70 December 2018 through two health facility-based surveillance networks in Kenya as detailed 71 previously [13]. The first involved continuous countrywide surveillance for influenza through 72 severe acute respiratory illness (SARI) sentinel hospital reporting undertaken at six sites 73 supported by the Centers for Disease Control (CDC)-Kenya Country office: Kenyatta National 74 Hospital (KNH), Nakuru County and Referral Hospital (CRH), Nyeri CRH, Kakamega CRH,

Siaya CRH, and Coast General Teaching and Referral Hospital [7, 8, 13-16]. The second was
the pediatric viral pneumonia surveillance undertaken at Kilifi County Hospital (KCH) [12].

77

78 In the CDC-supported surveillance sites (CDC-Kenya), SARI was defined as acute onset of 79 illness (within the last 14 days) among hospitalized patients of all ages with cough and reported 80 fever (feverish) or a recorded temperature of \geq 38°C. Demographics, underlying diseases, and 81 signs and symptoms were collected from patients who met the case definition; the patients were 82 also assessed by study clinicians on physical and clinical findings. Furthermore, among 83 hospitalized children aged <5 years, additional clinical information including difficulty in 84 breathing, lower chest wall indrawing, inability to drink or breastfeed, and nasal flaring were 85 recorded. Chart review was done at the time of discharge or death to collect clinical outcome 86 data. In the second facility-based surveillance undertaken at KCH from January 2009 through 87 December 2018, a definition of pediatric viral pneumonia among children aged 1 day to 59 88 months presenting with syndromic severe or very severe pneumonia was used. A history of 89 cough for <30 days or difficulty breathing, when accompanied by lower chest wall indrawing 90 was defined as severe pneumonia; a history of cough for <30 days or difficulty breathing, when 91 accompanied by any one of prostration (including inability to feed or drink), coma, or 92 hypoxemia (oxygen saturation <90%) was defined as very severe pneumonia [7, 16].

93

We selected a total of 418 (31.9%) A(H1N1)pdm09 virus positive SARI samples for this analysis based on real-time reverse-transcription (RT)-PCR cycle threshold (Ct) of <35.0 (as proxy for high viral load), adequate sample volume for RNA extraction (>140 μ L), and balanced distribution of samples based on surveillance sites and years. We also identified a total of 157 IAV positive specimens from the KCH surveillance site. These were not

subsequently subtyped for influenza A(H1N1)pdm09 and A(H3N2) viruses. Therefore, weutilized all these specimens in the current analysis.

101

102 RNA extraction and multi-segment real-time PCR (M-RTPCR) for IAV. We performed 103 viral nucleic acid extraction from IAV and A(H1N1)pdm09 virus positive samples using the 104 QIAamp Viral RNA Mini Kit (Qiagen). We then reverse transcribed the extracted RNA, and 105 amplified the complete coding region of IAV genome in a single M-RTPCR using the Uni/Inf 106 primer set [17]. We evaluated successful amplification by running the products on 2% agarose 107 gel and visualized the reaction on a UV transilluminator after staining with RedSafe Nucleic 108 Acid Staining solution (iNtRON Biotechnology Inc.,).

109

110 IAV NGS and virus genome assembly. Following PCR, we purified the amplicons with 1X 111 AMPure XP beads (Beckman Coulter Inc., Brea, CA, USA), quantified amplicons with Quant-112 iT dsDNA High Sensitivity Assay (Invitrogen, Carlsbard, CA, USA), and normalized 113 amplicons to 0.2 ng/ μ L. We generated indexed paired-end libraries from 2.5 μ L of 0.2 ng/ μ L 114 amplicon pool using Nextera XT Sample Preparation Kit (Illumina, San Diego, CA, USA) 115 following the manufacturer's protocol. We then purified amplified libraries using 0.8X 116 AMPure XP beads, quantitated libraries using Quant-iT dsDNA High Sensitivity Assay 117 (Invitrogen, Carlsbard, CA, USA), and evaluated libraries for fragment size in the Agilent 2100 118 BioAnalyzer System using the Agilent High Sensitivity DNA Kit (Agilent Technologies, Santa 119 Clara, CA, USA). We diluted the libraries to 2nM in preparation for pooling and denaturation 120 for running on the Illumina MiSeq (Illumina, San Diego, CA, USA). We then NaOH denatured 121 pooled libraries, diluted libraries to 12.5 pM, and sequenced on the Illumina MiSeq using 2 x 122 250 bp paired end reads with the MiSeq v2 500 cycle kit (Illumina, San Diego, CA, USA). We 123 added five percent Phi-X (Illumina, San Diego, CA, USA) spike-in to the libraries to increase

library diversity by creating a more diverse set of library clusters. We carried out contiguous
(contigs) nucleotide sequence assembly from the sequence data using the FLU module of the
Iterative Refinement Meta-Assembler (IRMA) using IRMA default settings. We deposited all
the generated sequence data in the Global Initiative on Sharing All Influenza Data (GISAID)
EpiFluTM database (https://platform.gisaid.org/epi3/cfrontend).

129

130 Phylogenetic clustering and genetic group classification. We aligned and translated 131 consensus nucleotide sequences for all gene segments in AliView version 1.26 132 (https://ormbunkar.se/aliview/). We then reconstructed Maximum-likelihood (ML) trees for 133 the individual gene segments using IQ-TREE version 2.0.7 (http://www.iqtree.org/). The 134 software initiates tree reconstruction after assessment and selection of the best model of 135 nucleotide substitution for alignment. We linked the ML trees to various metadata and 136 visualized using R ggtree version 2.4.2 in R programming software v4.0.2 137 (http://www.rstudio.com/). We used the codon-complete hemagglutinin (HA) sequences of all 138 virus virus to characterize A(H1N1)pdm09 virus strains into genetic groups (i.e., clades, subclades, 139 and subgroups) using Phylogenetic Clustering using Linear Integer Programming (PhyCLIP) 140 v2.0 (https://github.com/alvinxhan/PhyCLIP). We downloaded vaccine strains and reference viruses from GISAID EpiFluTM database (https://platform.gisaid.org/epi3/cfrontend). We 141 142 aligned and reconstructed ML trees using vaccine strains, reference viruses, and translated 143 Kenyan A(H1N1)pdm09 viruses.

144

Genetic characterization of amino acid substitutions in surface glycoproteins, matrix, and non-structural proteins. We aligned the hemagglutinin (HA) and neuraminidase (NA) glycoproteins, matrix (M2), and non-structural 1 (NS1) gene segments of A(H1N1)pdm09 virus from this study using MAFFT version 7.475 (https://mafft.cbrc.jp/alignment/software/).

149 We identified the amino acid substitutions in the antigenic epitopes (Sa, Sb, Ca₁, Ca₂ and Cb) 150 [18], receptor binding sites (RBS), and potential glycosylation sites of HA1 subunit of HA 151 protein and substitutions in the codon-complete HA, NA, M2, and NS1 protein sequences of 152 A(H1N1)pdm09 viruses using Flusurver (https://flusurver.bii.a-star.edu.sg; accessed on June 153 01, 2021). We generated highlighter plots of Kenyan and reference sequences (obtained from the Global Initiative on Sharing All Influenza Data (GISAID) EpiFluTM database -154 155 https://platform.gisaid.org/epi3/cfrontend) using inhouse python scripts to visualize amino acid 156 differences in M2 and NS1 protein sequences among the sampled viruses.

157

158 Predictors of severe infection among hospitalized children aged <5 years. We used 159 multivariable logistic regression in Stata version 16 (Stata Corp, College Station, Texas, USA) 160 to investigate the predictors of severe infection among hospitalized patients. Only samples 161 collected from hospitalized children aged <5 years from CDC-Kenya and KCH surveillance 162 were used to estimate the predictors of severe infection. Children hospitalized with fever and 163 acute cough were categorized as severe if they had breathing difficulty and/or lower chest wall 164 indrawing, or otherwise non-severe. The predictors investigated included patient age 165 (categorized as <12 months, 12-23 months, and \geq 24 months), location of surveillance sites, 166 year of A(H1N1)pdm09 virus sampling (pandemic period, 2009-10; post pandemic period, 167 2011 onwards), A(H1N1)pdm09 virus genetic group, antigenic epitope substitutions, NS1 168 protein substitutions, and Ct values as proxy for viral load distributed in tertiles.

169

Ethics. Ethical clearance for the study was granted by the Kenya Medical Research Institute
(KEMRI) Scientific Steering Committee (SSC# 1899, 2558, and 2692) and KEMRI Wellcome Trust Research Programme Scientific and Ethical Review Unit (SERU# 1055, 1433, and 3044). Informed consent was sought and received from the study participants for the study.

174 **Results**

175	IAV sequencing and genome assembly. We generated and analyzed a total of 383
176	A(H1N1)pdm09 virus genome sequences. Among 418 A(H1N1)pdm09 virus positive samples
177	from the CDC-Kenya surveillance system, 414 (99.1%) passed pre-sequencing quality control
178	checks, which generated 344 (83.1%) codon-complete A(H1N1)pdm09 virus genome
179	sequences on the MiSeq. Of the 157 IAV positive specimens available from KCH, 94 (59.9%)
180	passed pre-sequencing quality control checks generating 45 (47.9%) A(H1N1)pdm09 virus (39
181	codon-complete and 6 partial) and 49 (52.1%) A(H3N2) virus genome sequences (46 codon-
182	complete and 3 partial). For this report, only the 39 codon-complete A(H1N1)pdm09 virus
183	sequences were included in the analyses. The sociodemographic and clinical characteristics of
184	these patients are shown in Table 1.

186 **Table 1.** Sociodemographic and clinical characteristics of hospitalized patients in severe acute

		SARI surveillance		Viral pneumonia surveillance	
		n	%	n	%
Age	0-11 months	73	21.2	18	46.2
	12-59 months	203	59.0	21	53.8
	>=5 years	68	19.8		
Gender	Female	141	41.0	14	35.9
	Male	203	59.0	25	64.1
Fever	No			1	2.6
	Yes	344	100.0	38	97.4
Cough	No			1	2.6
	Yes	344	100.0	38	97.4
Breathing difficulty	No	244	70.9	2	5.1
	Yes	100	29.1	37	94.9
In-drawing‡	No	144	41.9	1	2.6
	Yes	83	24.1	38	97.4
Nasal flaring‡	No	158	45.9	13	33.3
	Yes	82	23.8	26	66.7
Unable to drink/breastfeed‡	No	188	54.7	4	10.3
,	Yes	26	7.6	35	89.7
Lethargic‡	No	141	41.0	4	10.3
•	Yes	89	25.9	35	89.7
Wheezing	No	133	38.7	4	10.3
	Yes	10	2.9	35	89.7
Oxygen saturation	<90	29	8.4	6	15.4
	>=90	128	37.2	33	84.6
Intensive Care Unit	No	63	18.3		
	Yes	15	4.4		
Outcome	Death	8	2.3		
	Discharged	176	51.2		
	Absconded	4	1.2		

187 respiratory illness (SARI) and viral pneumonia surveillances in Kenya, 2009-18.

188

189 ‡ Chest in-drawing, nasal flaring, unable to drink/breastfeed at all, and lethargy in patients aged <5

190 years in SARI surveillance. SARI, severe acute respiratory illness.

192 Circulation of A(H1N1)pdm09 virus strains in Kenya and their patterns of antigenic

193 drift. Phylogenetic analyses revealed that multiple genetic groups of influenza 194 A(H1N1)pdm09 virus circulated in Kenya over the study period and evolved away from their 195 vaccine strain, Figure 1. All Kenyan viruses from 2009-18 evolved away from the vaccine 196 A/California/07/2009 (H1N1pdm09)-like strains virus and A/Michigan/45/2015 197 (H1N1pdm09)-like virus. The A(H1N1)pdm09 virus strains from 2009 to 2016 (n=324; 198 84.6%) evolved away from the 2009-17 Northern Hemisphere (NH) and 2009-16 Southern 199 Hemisphere (SH) vaccine strain A/California/07/2009 (H1N1pdm09)-like virus and fell into 200 clade 7 (n=97, 25.3%), clade 6 (n=132, 34.5%), subclade 6C (n=10, 2.6%), subclade 6B (n=47, 201 12.3%), and subclade 6B.1 (n=38, 9.9%), respectively. All the viruses from 2018 evolved away 202 from the 2017-18 NH and 2017 SH vaccine strain A/Michigan/45/2015 (H1N1pdm09)-like 203 virus and fell into subgroup 6B.1A (n=57, 14.9%) and subgroup 6B.1A1 (n=2, 0.5%), 204 respectively.



206

Figure 1. Maximum-likelihood phylogenetic tree of A(H1N1)pdm09 virus sequences from Kenya collected between 2009 and 2018, A(H1N1)pdm09 virus vaccine strains, and reference viruses. This is a time-calibrated phylogenetic tree with time shown on the x-axis. Branches are colored based on Kenyan, vaccine, and reference strains as shown in the color key. Amino acid substitutions in HA1 and HA2 subunits, which define A(H1N1)pdm09 virus genetic groups are also shown (HA2 substitutions

are labelled in purple as shown in the color key).

213	Clades 6 and 7 viruses co-circulated in Kenya between 2009 and 2012, with clade 6 viruses
214	carrying HA substitutions D97N, S185T, and S203T, while clade 7 viruses carried HA
215	substitutions D97, S185, and S203T, Figure 1. Clade 6 viruses evolved into subclades 6A, 6B,
216	and 6C; 6C carrying HA substitution V234I circulated in Kenya in 2013-14, while 6B with HA
217	substitutions K163Q, A256T, and K283E circulated in Kenya in 2014-16. Subclade 6B evolved
218	further into subgroup 6B.1 carrying additional HA substitution S84N, which dominated in
219	2015-16. Subgroup 6B.1 further evolved into subgroups 6B.1A and 6B.1A1 carrying HA
220	substitutions S74R, S164T, and I295V that dominated in 2018.

221

222 Comparison of the deduced amino acid sequences of the viruses identified in hospitalized 223 patients relative to the vaccine strains from which all the 2009-18 strains considerably evolved 224 revealed significant amino acid substitutions in antigenic epitopes and RBS among the 225 circulating A(H1N1)pdm09 virus strains (Table 2). There were 13 amino acid substitutions 226 across the five antigenic sites among sampled Kenyan viruses. Ranking from the most variable 227 site, Sa, Ca₂, Sb, Ca₁, and Cb had two, six, six, three, and one substitution, respectively. The 228 most frequent HA substitution per site for Sa, Sb, Ca₁, Ca₂ and Cb was K163Q, S185T, S203T, 229 A141E, and S74R, respectively. HA substitutions S203T and S185T were the most dominant 230 substitutions occurring in 100% and 59.3% (227/383) viruses from 2009-18, respectively. In 231 addition, we observed previously described HA substitutions at the RBS (A186T and D222E) 232 and glycosylation sites (A186T and N125S) of the viruses.

Season	Vaccine (Genetic group); hemisphere ‡	Number of Kenyan viruses analyzed (year of sampling)	Amino acid substitutions †
2009-2017	A/California/07/2009 (clade 1); NH	324 (2009-2016)	P137S ^d , A139V ^d , A141T ^d , K142R ^d , K163Q ^a , G170R ^c , S185T ^b , S185A ^b , S185I ^b , A186T ^b , A186V ^b , D187N ^b , S203T ^c , R205K ^c , D222E, D222N
2009-2016	A/California/07/2009 (clade 1); SH	324 (2009-2016)	P137S ^d , A139V ^d , A141T ^d , K142R ^d , K163Q ^a , G170R ^c , S185T ^b , S185A ^b , S185I ^b , A186T ^b , A186V ^b , D187N ^b , S203T ^c , R205K ^c , D222E, D222N
2017-2018	A/Michigan/45/2015 (6B.1); NH	59 (2018)	S74R°, P137S ^d , A141E ^d , S164T ^a
2017	A/Michigan/45/2015 (6B.1); SH	59 (2018)	S74R ^e , P137S ^d , A141E ^d , S164T ^a

234	Table 2. Antigenic drift among A(H1N1)pdm09 virus strains collected from Kenya, 2009-18.
235	

236

237 NH, Northern Hemisphere; SH, Southern Hemisphere.

²³⁸ † A (H1N1)pdm09 antigenic sites are represented as Sa-a; Sb-b; Ca₁-c; Ca₂-d; and Cb-e.

239 ‡ Recommended vaccines for each influenza season are adopted from Global Initiative on Sharing All

240 Influenza Data (GISAID) (<u>https://www.gisaid.org/resources/human-influenza-vaccine-composition/</u>).

241 242

Genetic and antigenic characterization of NA, M2, and NS1 proteins. All NA proteins lacked the H275Y marker associated with resistance to neuraminidase inhibitors. However, seven (1.8%) NA proteins had substitutions T362I (3), I117M (3), and V234I (1). Additionally, all the Kenyan viruses contained the adamantine-resistance marker S31N, Figure 2. All 59 viruses from 2018 had six amino acid substitutions (E55K, L90I, I123V, E125D, K131E, and N205S) in NS1 protein, Figure 3.



Figure 2. Highlighter plot of M2 protein sequences of A(H1N1)pdm09 viruses from Kenya showing the adamantine-resistance marker S31N amino acid substitution in M2 protein. The substitution was observed in all the A(H1N1)pdm09 viruses collected in Kenya between 2009 and 2018. Sequences were aligned with A/Brisbane/59/2007.

- 258
- 259



202

263

Figure 3. Highlighter plot of NS1 protein sequences of A(H1N1)pdm09 viruses from Kenya showing the NS1 protein substitutions: E55K, L90I, I123V, E125D, K131E, and N205S. The sequences were aligned with vaccine strain A/California/07/2009. The substitutions were reported for 59 virus sequences collected from hospitalized patients in 2018 from CDCsupported surveillance and KCH pediatric viral pneumonia surveillance. CDC, Centers for Disease Control; KCH, Kilifi County Hospital.

271 Predictors of severe infection among hospitalized children aged <5 years. We observed

- that severity of infection reduced with increase in age. Children aged ≥ 24 months were less
- 273 likely to have severe infection compared to children aged 0-11 months (adjusted odds ratio
- 274 (aOR), 0.25; 95% CI, 0.11-0.54) and that A(H1N1)pdm09 viruses of subclade 6B and clade 7
- were less likely associated with severe infection compared to clade 6 viruses (aOR, 0.25; 95%)
- 276 CI, 0.09-0.72) and (aOR, 0.34; 95% CI, 0.15-0.79), respectively (**Table 3**). Ct value, year of
- sampling, location of sampling, antigenic epitope substitutions, and NS1 protein substitutions
- 278 were not associated with severe infection.

280 **Table 3.** Predictors of severe infection among hospitalized children aged <5 years.

281

Characteristics	Severe, N=161	Non-severe. N=108	aOR (95% CI)	p-value
	n (%)	n (%)		
Age				
<12 months	68 (42.2)	20 (18.5)	Ref 0.61	
12-23 months	58 (36.0)	29 (25.9)	(0.28,1.32) 0.25	0.21
≥24 months	35 (21.7)	59 (54.6)	(0.11,0.54)	<0.01
Ct value (tertiles)				
<22.5	42 (26.1)	42 (38.9)	Ref	
22.5-25.5	46 (28.6)	41 (38.0)	0.87 (0.40,1.87)	
>25.5	73 (45.3)	25 (23.2)	1.64 (0.76,3.53)	
Year				
Pandemic	44 (27.3)	32 (29.6)		
Post-pandemic	117 (72.7)	76 (70.4)		
Location				
Kakamega	15 (9.3)	21 (19.4)	Ref	
Kilifi	39 (24.2)	0 (0)	-	
Mombasa	5 (3.1)	0 (0)	-	
	- (-)	- (-)	1.60	
Nairobi	33 (20.5)	19 (17.6)	(0.56,4.60)	0.38
	/	/>	1.38	
Nakuru	36 (22.4)	38 (35.2)	(0.54,3.56)	0.5
Nveri	18 (11 2)	22 (20 4)	1.78	0.29
Nyen	10 (11.2)	22 (20.4)	2.01	0.25
Siaya	15 (9.3)	8 (7.4)	(0.55,7.31)	0.29
Genetic group				
Clade 6	55 (34.2)	23 (21.3)	Ref	
			0.25	
Subclade 6B	14 (8.7)	25 (23.2)	(0.09,0.72)	0.01
	22 (40.0)	F (4 C2)	2.68	0.14
Subclade 6B.1	32 (19.9)	5 (4.63)	(0.81,8.94)	0.11
Subgroup 6B.1A	31 (19.3)	21 (19.4)	(0.24.1.58)	0.31
Subgroup 6B.1A1	2 (1.2)	0 (0)	(===)====)	
5008.00p 00.1/11	2 (1.2)	0 (0)	0.68	
Subclade 6C	4 (2.5)	2 (1.9)	(0.08,5.90)	0.72
			0.34	
Clade 7	23 (14.3)	32 (29.6)	(0.15,0.79)	0.01
Antigenic substitution				
Yes	99 (61.5)	70 (64.8)		
No	62 (38.5)	38 (35.2)		
NS1 gene substitution				
Yes	33 (20.5)	21 (19.4)		
No	128 (79.5)	87 (80.6)		

282

aOR, adjusted odds ratio; CI, confidence interval; Ct; cycle threshold.

284 Discussion

285 We observed that A(H1N1)pdm09 viruses circulating in Kenya from 2009-18 evolved away 286 from their vaccine strain over the study period. Kenyan virus strains from 2009-16 evolved 287 away from the 2009-17 NH and 2009-16 SH vaccine strain A/California/07/2009 288 (H1N1pdm09)-like virus and fell into clades 7 and 6, and subclades 6C, 6B, and 6B.1, 289 respectively. All viruses from 2018 evolved away from the 2017-18 NH and 2017 SH vaccine 290 strain A/Michigan/45/2015 (H1N1pdm09)-like virus and fell into subgroups 6B.1A and 291 6B.1A1, respectively. We identified considerable amino acid substitutions in antigenic 292 epitopes and RBS among the circulating viruses, which confirms the continued evolution of 293 circulating influenza viruses in Kenya. We recently reported that the evolutionary dynamics of 294 A(H1N1)pdm09 virus in Kenya was associated with multiple virus introductions into the 295 country between 2009 and 2018, although only a few of those introductions instigated local 296 seasonal epidemics that then established local transmission clusters across the country [13]. 297 We also observed substitutions in NA protein, which have been associated with reduced 298 susceptibility to neuraminidase inhibitors in vitro [19], substitutions in M2 protein associated 299 with adamantine-resistance, and substitutions in NS1 protein that possibly result in increased 300 virulence [20]. Nonetheless, we were not able to associate viral genetic changes and 301 substitutions with increased severity.

302

Analysis of virus sequence data from Kenya during the pandemic in 2009 identified the introduction of clades 2 and 7 viruses into Kenya [21]. We recently confirmed these findings and showed that clades 6 and 7 viruses were introduced into Kenya, disseminated countrywide, and persisted across multiple epidemics as local transmission clusters [13]. A recent study from Kenya reported the circulation of clade 6B, subclade 6B.1, and subclade 6B.2 viruses in the 2015-18 influenza seasons [22]. Here, through detailed genomic analysis, we extend these

309 observations and show that multiple influenza strains were introduced into Kenya and spread 310 countrywide over the study period. Most of the amino acid substitutions associated with the 311 continued evolution of A(H1N1)pdm09 viruses in Kenya have also been reported in other 312 studies in Africa [22-25] and Asia [26, 27]. Therefore, the continuing evolution of 313 A(H1N1)pdm09 viruses in Kenya is in part due to the global circulation of influenza viruses.

314

315 The genetic diversity of A(H1N1)pdm09 viruses in specific regions arising from multiple virus 316 introductions and subsequent establishment of local transmission clusters [13] composed of 317 viruses harboring considerable amino acid substitutions in antigenic epitopes and RBS could 318 lead to predominance of circulating viruses that are not closely matched to previously selected 319 vaccine strains as shown in our study. In countries like Kenya, where influenza virus spread is 320 year-round [9], there also exists unpredictability of which genetic virus strain may predominate 321 and when. Influenza vaccines with broad coverage ("universal" vaccines) could be key to 322 managing the influenza disease burden in such settings. Currently, Kenya does not have a 323 national influenza vaccination policy [28], but it would be important to consider deployment 324 of quadrivalent influenza vaccines with representative A(H1N1)pdm09 virus, A(H3N2) virus, 325 and both influenza B virus lineages (B/Victoria and B/Yamagata) for optimal vaccine 326 effectiveness [13, 29, 30]. It will also be important to investigate further whether the use of SH 327 or NH formulated vaccines could have a place in tropical regions like in Kenya, where virus 328 importations from both hemispheres are common.

329

330 Specific influenza virus gene segment phylogenies and genetic group memberships have been 331 associated with disease severity [31]. Although we did not observe associations between 332 genetic group membership or substitutions with disease severity, these findings underscore the 333 importance of reporting genetic surveillance data along with epidemiological data to allow for

analysis of factors that may increase risk of influenza and impact disease severity [32].
Although we did not observe association between viral load and disease severity, larger studies
have reported this association among hospitalized patients with pneumonia infection [33],
which underscores the need for multi-site studies with improved statistical power to estimate
associations. We reported a reduction in disease severity with increase in age in children aged
<5 years, which corroborates the evidence that children aged <6 months may experience more
severe influenza related complications [34].

341

342 The study had some limitations. First, the analysis in this report only involved the HA, NA, 343 M2, and NS1 gene segments of A(H1N1)pdm09 virus. Although these regions are important 344 in understanding antigenic drift and antiviral drug resistance in influenza viruses, important 345 changes in other gene segments, for example, mutations associated with increased 346 pathogenicity may not have been captured. Secondly, the prioritized samples were selected 347 based on anticipated probability of successful sequencing inferred from the sample's viral load 348 as indicated by the diagnosis Ct value. Such a strategy ultimately avoided NGS of some 349 samples that may have been critical in inferring additional genetic characteristics of circulating 350 influenza viruses. Lastly, the analysis in this report did not include phenotypic analyses to 351 assess the effect of observed substitutions on virulence, pathogenicity, and transmissibility of 352 influenza viruses.

353

In conclusion, our study highlights the utility of genomic surveillance to monitor the evolutionary changes of influenza viruses within a country and the utility of combined genetic and epidemiological data to improve understanding of influenza season severity and guide intervention. Routine influenza surveillance with broad geographic representation and whole

- 358 genome sequencing capacity to inform on the severity of circulating strains could improve
- 359 selection of influenza strains for inclusion in vaccines.

361 Supporting information

362 **Conflict of interest.** None

363

364 **Disclosure.** The findings and conclusions in this report are those of the authors and do not

365 necessarily represent the official position of the Centers for Disease Control and Prevention.

367	Funding: The authors D.C.O. and C.N.A. were supported by the Initiative to Develop African
368	Research Leaders (IDeAL) through the DELTAS Africa Initiative [DEL-15-003]. The
369	DELTAS Africa Initiative is an independent funding scheme of the African Academy of
370	Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and
371	supported by the New Partnership for Africa's Development Planning and Coordinating
372	Agency (NEPAD Agency) with funding from the Wellcome Trust [107769/Z/10/Z] and the
373	UK government. The study was also part funded by a Wellcome Trust grant [1029745] and the
374	USA CDC grant [GH002133]. This paper is published with the permission of the Director of
375	KEMRI.

376 **References**

377 1. Garten, R.J., et al., Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) 378 influenza viruses circulating in humans. Science, 2009. **325**(5937): p. 197-201. 379 2. Dawood, F.S., et al., Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in 380 Humans. New England Journal of Medicine, 2009. 360(25): p. 2605-2615. 381 3. Smith, G.J., et al., Origins and evolutionary genomics of the 2009 swine-origin H1N1 382 influenza A epidemic. Nature, 2009. 459(7250): p. 1122-5. 383 4. Baillie, G.J., et al., Evolutionary dynamics of local pandemic H1N1/2009 influenza 384 virus lineages revealed by whole-genome analysis. J Virol, 2012. 86(1): p. 11-8. 385 5. Zehender, G., et al., Reconstruction of the evolutionary dynamics of the A(H1N1)pdm09 386 influenza virus in Italy during the pandemic and post-pandemic phases. PLoS One, 387 2012. **7**(11): p. e47517. 388 6. Venter, M., et al., Evolutionary dynamics of 2009 pandemic influenza A virus subtype 389 H1N1 in South Africa during 2009-2010. J Infect Dis, 2012. 206 Suppl 1: p. S166-72. 390 7. Katz, M.A., et al., Results From the First Six Years of National Sentinel Surveillance 391 for Influenza in Kenya, July 2007–June 2013. PLoS ONE, 2014. 9(6): p. e98615. 392 8. Emukule, G.O., et al., The burden of influenza and RSV among inpatients and 393 outpatients in rural western Kenya, 2009-2012. PLoS One, 2014. 9(8): p. e105543. 394 9. Emukule, G.O., et al., Influenza activity in Kenya, 2007-2013: timing, association with 395 climatic factors, and implications for vaccination campaigns. Influenza and Other 396 Respiratory Viruses, 2016. 10(5): p. 375-385. 397 10. Lemey, P., M. Suchard, and A. Rambaut, *Reconstructing the initial global spread of a* 398 human influenza pandemic: a Bayesian spatial-temporal model for the global spread 399 of H1N1pdm. PLoS Curr Biol, 2009. 1(RRN1031). 400 11. Rambaut, A. and E. Holmes, The early molecular epidemiology of the swine-origin 401 A/H1N1 human influenza pandemic. PLoS Currents, 2009. 1: p. RRN1003. 402 12. Nokes, D.J., et al., Incidence and severity of respiratory syncytial virus pneumonia in 403 rural Kenyan children identified through hospital surveillance. Clin Infect Dis, 2009. 404 **49**(9): p. 1341-9. 405 13. Owuor, D.C., et al., Characterizing the Countrywide Epidemic Spread of Influenza 406 A(H1N1)pdm09 Virus in Kenya between 2009 and 2018. Viruses, 2021. 13(10): p. 407 1956. 408 14. Katz, M.A., et al., Epidemiology, Seasonality, and Burden of Influenza and Influenza-409 Like Illness in Urban and Rural Kenya, 2007-2013;2010. The Journal of Infectious 410 Diseases, 2012. 206: p. S53-S60. 411 15. Feikin, D.R., et al., The burden of common infectious disease syndromes at the clinic 412 and household level from population-based surveillance in rural and urban Kenya. 413 PLoS One, 2011. 6(1): p. e16085. 414 16. Emukule, G.O., et al., The Epidemiology and Burden of Influenza B/Victoria and 415 B/Yamagata Lineages in Kenya, 2012-2016. Open forum infectious diseases, 2019. 416 **6**(10): p. ofz421-ofz421. 417 17. Zhou, B. and D.E. Wentworth, Influenza A virus molecular virology techniques. 418 Methods Mol Biol, 2012. 865: p. 175-92. 419 18. A.J., C., et al., The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin 420 (*H1 subtype*). Cell, 1982. **31**(2 Pt 1): p. 417-427. 421 19. Nguyen, H.T., A.M. Fry, and L.V. Gubareva, Neuraminidase inhibitor resistance in 422 influenza viruses and laboratory testing methods. Antivir Ther, 2012. 17(1 Pt B): p. 423 159-73.

424 425	20.	Clark, A.M., et al., Functional Evolution of Influenza Virus NS1 Protein in Currently Circulating Human 2009 Pandemic H1N1 Viruses, J Virol, 2017, 91 (17).
426	21.	Gachara, G., et al., Whole genome characterization of human influenza A(H1N1)pdm09
427		viruses isolated from Kenva during the 2009 pandemic. Infect Genet Evol. 2016. 40: p.
428		98-103.
429	22.	Opanda, S., et al., Assessing antigenic drift and phylogeny of influenza A (H1N1) pdm09
430		virus in Kenva using HA1 sub-unit of the hemagelutinin gene. PLoS One. 2020. 15(2):
431		p. e0228029.
432	23.	Monamele, C.G., et al., Molecular characterization of influenza A(H1N1)pdm09 in
433		Cameroon during the 2014-2016 influenza seasons. PLoS One. 2019. 14(1): p.
434		e0210119.
435	24.	Dia, N., et al., A subregional analysis of epidemiologic and genetic characteristics of
436		influenza A(H1N1)pdm09 in Africa: Senegal. Cape Verde. Mauritania, and Guinea.
437		2009-2010. Am J Trop Med Hyg, 2013. 88 (5): p. 946-53.
438	25.	Byarugaba, D.K., et al., Whole-genome analysis of influenza A(H1N1)pdm09 viruses
439		isolated in Uganda from 2009 to 2011. Influenza Other Respir Viruses, 2016. 10(6): p.
440		486-492.
441	26.	Mukherjee, A., et al., Genetic Characterization of Circulating 2015 A(H1N1)pdm09
442		Influenza Viruses from Eastern India. PLoS One, 2016. 11(12): p. e0168464.
443	27.	Jones, S., et al., Evolutionary, genetic, structural characterization and its functional
444		implications for the influenza A (H1N1) infection outbreak in India from 2009 to 2017.
445		Sci Rep, 2019. 9 (1): p. 14690.
446	28.	Dawa, J., et al., Developing a seasonal influenza vaccine recommendation in Kenya:
447		Process and challenges faced by the National Immunization Technical Advisory Group
448		(NITAG). Vaccine, 2019. 37 (3): p. 464-472.
449	29.	Owuor, D.C., et al., Genetic characterization of influenza A(H3N2) viruses circulating
450		in coastal Kenya, 2009-2017. Influenza and Other Respiratory Viruses, 2020. 14(3): p.
451		320-330.
452	30.	Nyasimi, F.M., et al., Epidemiological and evolutionary dynamics of influenza B virus
453		in coastal Kenya as revealed by genomic analysis of strains sampled over a single
454		season. Virus Evolution, 2020. 6(2).
455	31.	Goldstein, E.J., et al., Integrating patient and whole-genome sequencing data to
456		provide insights into the epidemiology of seasonal influenza A (H3N2) viruses.
457		Microbial Genomics, 2017. 4.
458	32.	Broberg, E., et al., Improving influenza virological surveillance in Europe: strain-
459		based reporting of antigenic and genetic characterisation data, 11 European countries,
460		influenza season 2013/14. Euro Surveill, 2016. 21(41).
461	33.	Feikin, D.R., et al., Is Higher Viral Load in the Upper Respiratory Tract Associated
462		With Severe Pneumonia? Findings From the PERCH Study. Clin Infect Dis, 2017.
463		64 (suppl_3): p. S337-S346.
464	34.	Lafond, K.E., et al., Global Role and Burden of Influenza in Pediatric Respiratory
465		Hospitalizations, 1982-2012: A Systematic Analysis. PLoS medicine, 2016. 13(3): p.
466		e1001977-e1001977.
467		